+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating the Move Sapiens virtual reality VR exergame combined with a short high-intensity interval training HIIT model as a potential intervention for adolescents aged 12 to 17 with Attention-Deficit Hyperactivity Disorder ADHD. This study aims to determine if this VR exercise game can improve attention, executive function, and reduce symptoms like sleep problems and anxiety compared to a control group. The trial also explores possible brain function changes in a smaller group using neuroimaging. Participants will be randomly assigned to either the experimental group, which practices the Move Sapiens VR exergame incorporating HIIT cycles of intense effort and rest, or the control group, which uses an adapted version of the game without physical exercise, interacting through a joystick. Both groups will complete 20 sessions over 4 weeks, with the first four and last sessions conducted in the lab under supervision where heart rate is monitored. The remaining sessions occur at home with remote monitoring, and game scores will be tracked throughout. During the study, participants will visit the clinic for assessments before and after the intervention, including attention and executive function tests as well as questionnaires on sleep and anxiety. Heart rate will be measured during lab sessions. Researchers will analyze changes in inattention and inhibitory control as primary outcomes, with secondary measures including working memory, cognitive flexibility, reaction time, sleep quality, anxiety symptoms, impulsivity, and attention. The study will last about 4 weeks with close monitoring and data collection from all participants.

Age: 12Years - 17YearsAll GendersPhase Not Applicable
2 locations
E

Actively Recruiting

This research aims to evaluate the effect of tozorakimab, given in addition to standard care, in adults hospitalized for viral lung infection who require supplemental oxygen. The study focuses on whether this treatment can prevent death or the need for invasive mechanical ventilation IMV or extracorporeal membrane oxygenation ECMO. It is a Phase III, randomized, double-blind, placebo-controlled trial assessing patients with hypoxaemia due to viral lung infection. Participants will be randomly assigned in equal numbers to one of two groups. One group will receive a single intravenous dose of tozorakimab on Day 1, while the other group will receive a matching placebo dose. Both groups will continue to receive standard care alongside the study treatment. The trial is designed to follow patients for up to 60 days to assess various clinical outcomes related to respiratory status and survival. During the study, participants will be monitored for progression to invasive ventilation or death up to 28 days as the primary outcome. Additional assessments include survival at 60 days, time spent outside the intensive care unit, days free from supplemental oxygen, and clinical progression scales. Safety evaluations include monitoring for anti-drug antibodies. The total participation time spans from treatment administration through clinical follow-up up to 60 days.

Age: 18Years +All GendersPhase 3
473 locations
C

Actively Recruiting

This research investigates whether a single intravenous esketamine infusion or a single Crisis Response Planning session, each added to enhanced treatment as usual, can reduce future suicide-related events among adolescents and adults aged 14 years or older. The study takes place within the public emergency care network in Indaiatuba, Brazil, focusing on individuals who have recently attempted suicide or have severe suicidal thoughts with intent to act. It also explores improvements in symptoms like depression, anxiety, sleep quality, and overall well-being over 12 months. Participants are randomly assigned to one of three groups one group receives an intravenous esketamine infusion at 0.375 mgkg over 40 minutes with medical monitoring, another group receives a single 20-to-45-minute Crisis Response Planning session with a trained clinician to develop a personalized safety plan, and the third group receives enhanced treatment as usual alone, which includes early outpatient psychiatric consultation and lethal means safety counseling. All groups continue to receive routine emergency care, and delivery of outpatient consultation and safety counseling is carefully documented. Throughout the study, participants complete assessments at several time points including enrollment, 24 hours, 7 days, and multiple weeks up to one year. Blood samples are collected at baseline to explore biological factors related to treatment response. Participants also use a smartphone app to answer questions about mood and suicidal thoughts during three separate 30-day periods. Safety monitoring, including contact after safety alerts through the app, continues during follow-up. The main outcome measured is the time to a first suicide-related event, such as an attempt or emergency care due to self-injury, with blinded adjudication of events. Rescue treatment combining esketamine and Crisis Response Planning may be offered after such events while participants remain in follow-up.

Age: 14Years +All GendersPhase 4
1 location